DE60039596D1 - Verfahren zur herstellung von monoklonalen antikörpern - Google Patents
Verfahren zur herstellung von monoklonalen antikörpernInfo
- Publication number
- DE60039596D1 DE60039596D1 DE60039596T DE60039596T DE60039596D1 DE 60039596 D1 DE60039596 D1 DE 60039596D1 DE 60039596 T DE60039596 T DE 60039596T DE 60039596 T DE60039596 T DE 60039596T DE 60039596 D1 DE60039596 D1 DE 60039596D1
- Authority
- DE
- Germany
- Prior art keywords
- monoclonal antibody
- preparation
- monoclonal antibodies
- hybridoma
- immortalized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8792999 | 1999-03-30 | ||
PCT/JP2000/002022 WO2000058499A1 (fr) | 1999-03-30 | 2000-03-30 | Procede pour la production d'anticorps monoclonal |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60039596D1 true DE60039596D1 (de) | 2008-09-04 |
Family
ID=13928616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60039596T Expired - Lifetime DE60039596D1 (de) | 1999-03-30 | 2000-03-30 | Verfahren zur herstellung von monoklonalen antikörpern |
Country Status (8)
Country | Link |
---|---|
US (1) | US8236530B2 (de) |
EP (1) | EP1167537B1 (de) |
AT (1) | ATE402267T1 (de) |
AU (1) | AU754808B2 (de) |
CA (1) | CA2368734C (de) |
DE (1) | DE60039596D1 (de) |
DK (1) | DK1167537T3 (de) |
WO (1) | WO2000058499A1 (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
PT1390389E (pt) | 2001-04-26 | 2009-04-03 | Biogen Idec Inc | Anticorpos que bloqueiam o cripto e as utilizações dos mesmos |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
EP2343320B1 (de) | 2005-03-25 | 2017-10-25 | GITR, Inc. | Anti-gitr antikörper und ihre verwendung |
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
EP1911766A1 (de) * | 2006-10-13 | 2008-04-16 | Glycotope Gmbh | Verwendung aus myeloischer Leukämie stammender humaner Zellen für die Exprimierung von Antikörpern |
ES2533964T5 (es) * | 2006-09-10 | 2024-05-09 | Glycotope Gmbh | Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos |
CN101588817B (zh) * | 2006-09-10 | 2013-06-12 | 葛莱高托普有限公司 | 骨髓白血病来源的细胞在抗体表达中的用途 |
AU2013203482B2 (en) * | 2006-09-10 | 2015-08-27 | Glycotope Gmbh | Fully human high yield production system for improved antibodies and proteins |
US20120282245A1 (en) | 2006-10-03 | 2012-11-08 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
EP1920781B1 (de) | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Zusammensetzungen die ein Core-1 positives Mikroorganismus enthalten und deren Verwendung zur Behandlung von Tumoren |
CA2676766A1 (en) | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
CA2680549A1 (en) | 2007-03-12 | 2008-09-18 | Alan D. D'andrea | Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents |
JP5932217B2 (ja) | 2007-07-12 | 2016-06-08 | ジーアイティーアール, インコーポレイテッド | Gitr結合分子を使用する併用療法 |
AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
AU2010258094B2 (en) | 2009-06-10 | 2013-09-05 | Stephen Sanig Research Institute Ltd. | Methods of generating cells exhibiting phenotypic plasticity |
WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
JP5887270B2 (ja) | 2009-09-02 | 2016-03-16 | ジェネンテック, インコーポレイテッド | 突然変異体smoothenedおよびその使用方法 |
AR078377A1 (es) | 2009-12-11 | 2011-11-02 | Genentech Inc | Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso |
MY159156A (en) | 2009-12-21 | 2016-12-15 | Genentech Inc | Antibody formulation |
DK2625197T3 (en) | 2010-10-05 | 2016-10-03 | Genentech Inc | Smoothened MUTANT AND METHODS OF USING THE SAME |
EP2748302B1 (de) | 2011-08-22 | 2018-08-15 | Glycotope GmbH | Mikroorganismen mit einem tumor-antigen |
AR095399A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida, método |
RU2707550C2 (ru) | 2013-03-13 | 2019-11-27 | Дженентек, Инк. | Составы со сниженным окислением |
US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
AR095396A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones de anticuerpo |
LT2968466T (lt) | 2013-03-13 | 2018-10-10 | F. Hoffmann-La Roche Ag | Sumažintos oksidacijos kompozicijos |
RU2015144020A (ru) | 2013-03-15 | 2017-04-21 | Дженентек, Инк. | Среды для культивирования клеток и способы получения антител |
SG11201507367PA (en) | 2013-03-15 | 2015-10-29 | Genentech Inc | Cell culture compositions with antioxidants and methods for polypeptide production |
SI3049441T1 (sl) | 2013-09-27 | 2020-03-31 | F. Hoffmann-La Roche Ag | Formulacije protiteles proti PD-L1 |
CA2933881A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
KR20240017102A (ko) | 2013-12-17 | 2024-02-06 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
KR20160099092A (ko) | 2013-12-17 | 2016-08-19 | 제넨테크, 인크. | Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법 |
JP6736467B2 (ja) | 2014-02-04 | 2020-08-05 | ジェネンテック, インコーポレイテッド | 平滑化変異体及びその使用方法 |
MX2016012779A (es) | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
CN106794247B (zh) | 2014-09-15 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
AU2015350242A1 (en) | 2014-11-17 | 2017-06-29 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
CA2975875A1 (en) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened and methods of using the same |
CA2986263A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
KR20180098625A (ko) | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | 분해가 감소된 폴리소르베이트를 갖는 제형 |
KR20180093078A (ko) | 2015-12-30 | 2018-08-20 | 제넨테크, 인크. | 단백질 제제를 위한 트립토판 유도체의 용도 |
CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
CN109071625A (zh) | 2016-02-04 | 2018-12-21 | 柯瑞斯公司 | 平滑化突变体和其使用方法 |
TWI759287B (zh) | 2016-03-15 | 2022-04-01 | 日商中外製藥股份有限公司 | 使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法 |
CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
JP2021524740A (ja) | 2018-05-18 | 2021-09-16 | グリコトープ ゲーエムベーハー | 抗muc1抗体 |
CA3103017A1 (en) | 2018-06-23 | 2019-12-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
MX2021000558A (es) | 2018-07-18 | 2021-04-13 | Genentech Inc | Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino. |
MX2021001453A (es) | 2018-08-08 | 2021-04-12 | Genentech Inc | Uso de derivados de triptofano y l-metionina para una formulacion de proteinas. |
CA3111809A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
AU2021293038A1 (en) | 2020-06-16 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating triple-negative breast cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) * | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6475787B1 (en) * | 1989-07-28 | 2002-11-05 | Wyeth | Method for producing monoclonal antibodies |
EP0746609A4 (de) * | 1991-12-17 | 1997-12-17 | Genpharm Int | Heterologe antikörper produzierende transgene nicht-humane tiere |
-
2000
- 2000-03-30 DE DE60039596T patent/DE60039596D1/de not_active Expired - Lifetime
- 2000-03-30 EP EP00912975A patent/EP1167537B1/de not_active Expired - Lifetime
- 2000-03-30 AT AT00912975T patent/ATE402267T1/de not_active IP Right Cessation
- 2000-03-30 DK DK00912975T patent/DK1167537T3/da active
- 2000-03-30 WO PCT/JP2000/002022 patent/WO2000058499A1/ja active IP Right Grant
- 2000-03-30 AU AU34563/00A patent/AU754808B2/en not_active Expired
- 2000-03-30 CA CA002368734A patent/CA2368734C/en not_active Expired - Lifetime
-
2005
- 2005-09-28 US US11/238,983 patent/US8236530B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US8236530B2 (en) | 2012-08-07 |
US20060059575A1 (en) | 2006-03-16 |
CA2368734C (en) | 2005-08-23 |
AU754808B2 (en) | 2002-11-28 |
CA2368734A1 (en) | 2000-10-05 |
AU3456300A (en) | 2000-10-16 |
ATE402267T1 (de) | 2008-08-15 |
EP1167537A4 (de) | 2005-05-04 |
EP1167537A1 (de) | 2002-01-02 |
EP1167537B1 (de) | 2008-07-23 |
WO2000058499A1 (fr) | 2000-10-05 |
DK1167537T3 (da) | 2008-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60039596D1 (de) | Verfahren zur herstellung von monoklonalen antikörpern | |
NZ324076A (en) | A composition comprising an immunoglobulin having an affinity constant for binding to predetermined human antigen and transgenic non-human animals capable of producing heterologous antibodies | |
DE602004002275D1 (de) | Verfahren zur herstellung rekombinanterpolyklonaler proteine | |
DE59007589D1 (de) | Verfahren zur Herstellung hetero-bispezifischer Antikörper. | |
ATE313633T1 (de) | Expressionsvektoren die für bispezifische proteine kodieren, und verfahren zur herstellung von biologisch-aktiven bispezifischen fusionsproteine in zellen von säugertieren | |
DE69000338T2 (de) | Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern. | |
DE3278203D1 (en) | Monoclonal antibodies specific for the human transferrin receptor glycoprotein | |
DE602004023965D1 (de) | Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen | |
CA2180425A1 (en) | Purified primate ctla-8 antigens and related reagents | |
ATE92959T1 (de) | Herstellung von chimaeren antikoerpern. | |
ATE366747T1 (de) | Menschliche monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor | |
DK0419858T3 (da) | Hunde-muse-heterohybridom og genfragment, som koder for den konstante region af hundeimmunglobuliner | |
DE50115580D1 (de) | Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus | |
Shulman et al. | Mutations affecting the structure and function of immunoglobulin M | |
BR9714401A (pt) | Antìgenos de supefìcie de célula de mamìfero; regentes relacionados | |
DE60014124D1 (de) | Antikörper, die spezifisch für fullerene sind | |
DE69025772T2 (de) | Verfahren zur herstellung von faktorabhängigen menschlichen b-zellinien | |
DE3581288D1 (de) | Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen. | |
PT733643E (pt) | Polipeptido proteico membranar possuindo funcao de suporte do crescimento de pre-celulas b e gene para este | |
ATE337395T1 (de) | Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper | |
EP0401370B1 (de) | Enzymimmuntest für menschliches typiv-collagen gemäss dem sandwichverfahren | |
ES2109225T3 (es) | Anticuerpos, su produccion y uso. | |
Raschke | Expression of murine IgM, IgD and Ia molecules on hybrids of murine LPS blasts with a Syrian hamster B lymphoma | |
DE3783002D1 (de) | Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega. | |
RU95109861A (ru) | Рекомбинантный фрагмент антитела, применение scfv, применение фрагмента антитела или пептида, способ получения scfv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: AMGEN FREMONT, INC. (N. D. GES. D. STAATES DEL, US Owner name: JAPAN TOBACCO INC., TOKIO/TOKYO, JP |
|
8364 | No opposition during term of opposition |